Sclerostin levels in uremic patients: a link between bone and vascular disease.

Sclerostin levels in uremic patients: a link between bone and vascular disease. Ren Fail. 2016 Mar 22;:1-6 Authors: Bruzzese A, Lacquaniti A, Cernaro V, Ricciardi CA, Loddo S, Romeo A, Montalto G, Costantino G, Torre F, Pettinato G, Salamone I, Aloisi C, Santoro D, Buemi M Abstract Sclerostin is a marker of low-turnover bone disease in end stage renal disease patients. The aim of this study was to evaluate serum sclerostin in uremic patients, analyzing its behavior during a single hemodialysis session. Twenty-one adult patients on intermittent hemodialysis treatment were enrolled. Acetate Free Bio-filtration (AFB) was the technique employed. Uremic patients were characterized by higher levels of serum sclerostin when compared with values observed in healthy subjects. Sclerostin assessed in pre-dialysis samples was 1.4 ± 1.02 ng/mL, whereas, in post dialysis samples, a reduction of sclerostin values was observed (0.8 ± 0.6 ng/mL; p: 0.008). Sclerostin correlated with parameters of dialysis adequacy, such as creatinine levels and Kt/V values, and it was significantly associated with atherosclerotic disease. Receiver operating characteristics analysis revealed a good diagnostic profile in identifying atherosclerotic disease. Sclerostin, a full dialyzable substance during AFB dialysis, is closely associated with atherosclerotic disease. Its reduction obtained through AFB could represent a defensive mechanism, improving vasc...
Source: Renal Failure - Category: Urology & Nephrology Tags: Ren Fail Source Type: research